| Trial ID: | L4517 |
| Source ID: | NCT05813249
|
| Associated Drug: |
Rybelsus Oral Product
|
| Title: |
Semaglutide in Nonalcoholic Fatty Liver Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Non-alcoholic Fatty Liver Disease
|
| Interventions: |
DRUG: Rybelsus Oral Product|DRUG: Ozempic Injectable Product|DRUG: Tocopherol and/or Actos
|
| Outcome Measures: |
Primary: NAFLD regression, improvement of severity of hepatic steatosis evaluated by CAP (dB/m), 48 weeks | Secondary: Fibrosis regression, improvement of liver stiffness evaluated by Fibroscan (kPa) and, 48 weeks
|
| Sponsor/Collaborators: |
Sponsor: Zagazig University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
180
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-02-15
|
| Completion Date: |
2024-04-01
|
| Results First Posted: |
|
| Last Update Posted: |
2024-04-02
|
| Locations: |
Zagazig University, Zagazig, Sharkia, 44519, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT05813249
|
